Stage IIIC Prostate Cancer AJCC v8 Active Not Recruiting Phase 1 Trials for Daratumumab (DB09331)

IndicationStatusPhase
DBCOND0109672 (Stage IIIC Prostate Cancer AJCC v8)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03177460Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate CancerTreatment